Triptans induce vasoconstriction of human arteries and veins from the thoracic wall

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 5, 2005, Pages 476-484

  Wackenfors, Angelica ^a   Jarvius, Malin ^a   Ingemansson, Richard ^a   Edvinsson, Lars ^a   Malmsjö, Malin ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Human; Migraine; Receptors; Serotonin; Triptan; Vasoconstriction

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 5 CARBAMOYLTRYPTAMINE; BRL 115572; ELETRIPTAN; KETANSERIN; MESSENGER RNA; NARATRIPTAN; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D AGONIST; SEROTONIN 1D ANTAGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; MALE; MAMMARY ARTERY; MIGRAINE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; THORAX DISEASE; THORAX WALL; VASOCONSTRICTION;

AGED; AGED, 80 AND OVER; ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; OXAZOLIDINONES; PIPERIDINES; POLYMERASE CHAIN REACTION; SEROTONIN AGONISTS; SUMATRIPTAN; THORAX; TRIAZOLES; TRYPTAMINES; VASOCONSTRICTION; VEINS;

EID: 18244369238     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000159639.59770.36     Document Type: Article

References (42)

1. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001;89:107-110.
2. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:1259-1287.
3. Ferrari MD. Migraine. Lancet. 1998;351:1043-1051.
4. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia. 1993;13:151-165.
5. Nilsson T, Longmore J, Shaw D, et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol. 1999;372:49-56.
6. Chester AH, Martin GR, Bodelsson M, et al. 5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries. Cardiovasc Res. 1990;24:932-937.
7. 2 receptor activation. Eur J Pharmacol. 1989;161:91-94.
8. Perren MJ, Feniuk W, Humphrey PP. The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia. 1989; 9(Suppl 9):41-46.
9. Deleu D, Hanssens Y. Current and emerging second-generation triptans in acute migraine therapy: a comparative review. J Clin Pharmacol. 2000;40: 687-700.
10. Humphrey PP. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol. 1991;238(Suppl 1):S38-S44.
11. Humphrey PP. How it started. Cephalalgia. 2001;21(Suppl 1):2-5.
12. Goadsby PJ. The pharmacology of headache. Prog Neurobiol. 2000;62: 509-525.
13. Bigal ME, Bordini CA, Antoniazzi AL, et al. The triptan formulations: a critical evaluation. Arq Neuropsiquiatr. 2003;61:313-320.
14. Bomhof M, Paz J, Legg N, et al. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol. 1999;42:173-179.
15. Pfaffenrath V, Cunin G, Sjonell G, et al. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache. 1998;38:184-190.
16. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997;49:1210-1218.
17. Visser WH, Jaspers NM, de Vriend RH, et al. Chest symptoms alter sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia. 1996;16:554-559.
18. Abbrescia VD, Pearlstein L, Kotler M. Sumatriptan-associated myocardial infarction: report of case with attention to potential risk factors. J Am Osteopath Assoc. 1997;97:162-164.
19. Welch KM, Mathew NT, Stone P, et al. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia. 2000;20:687-695.
20. Laine K, Raasakka T, Mantynen J, et al. Fatal cardiac arrhythmia after oral sumatriptan. Headache. 1999;39:511-512.
21. Kelly KM. Cardiac arrest following use of sumatriptan. Neurology. 1995; 45:1211-1213.
22. Dodick DW. Triptans and chest symptoms: the role of pulmonary vasoconstriction. Cephalalgia. 2004;24:298-304.
23. Parsons AA, Raval P, Smith S, et al. Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol. 1998;32:220-224.
24. van den Broek RW, Bhalla P, VanDenBrink AM, et al. Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization. Cephalalgia. 2002;22:83-93.
25. Wackenfors A, Ingemansson R, Malmsjo M. Endothelin receptors in endothelium-denuded human coronary artery bypass grafts and coronary arteries. Ann Thorac Surg. 2003;75:874-881.
26. van den Broek RW, Maassen VanDenBrink A, Mulder PG, et al. Comparison of contractile responses to donitriptan and sumatriptan in the human middle meningeal and coronary arteries. Eur J Pharmacol. 2002; 443:125-132.
27. MacIntyre PO, Bhargava B, Hogg KJ, et al. Effect of subcutaneous sumatriptan, a selective 5HT, agonist, on the systemic, pulmonary, and coronary circulation. Circulation. 1993;87:401-405.
28. van den Broek RW, Maassen VanDenBrink A, de Vries R, et al. Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol. 2000; 407:165-173.
29. 3 positron emission tomography. Neurology. 1997;48:1542-1550.
30. Gul H, Yildiz O, Simsek A, et al. Pharmacologic characterization of contractile serotonergic receptors in human isolated mesenteric artery. J Cardiovasc Pharmacol. 2003;41:307-315.
31. Reuter U, Salomone S, Ickenstein GW, et al. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia. 2004;24:398-407.
32. Resende AC, Tabellion A, Nadaud S, et al. Incubation of rat aortic rings produces a specific reduction in agonist-evoked contraction: effect of age of donor. Life Sci. 2004;76:9-20.
33. Banes AK, Watts SW. Upregulation of arterial serotonin 1B and 2B receptors in deoxycorticosterone acetate-salt hypertension. Hypertension. 2002;39:394-398.
34. 2 and 5-hydroxytryptamine in the radial artery compared to the internal thoracic artery. Gen Pharmacol. 2000;35:89-93.
35. 1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol. 1999;128:1133-1140.
36. 1B receptor. Br J Pharmacol. 1999;128: 730-734.
37. Pierce PA, Xie GX, Meuser T, et al. 5-Hydroxytryptamine receptor subtype messenger RNAs in human dorsal root ganglia: a polymerase chain reaction study. Neuroscience. 1997;81:813-819.
38. Hou M, Kanje M, Longmore J, et al. 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res. 2001; 909:112-120.
39. Pierce PA, Xie GX, Peroutka SJ, et al. Dual effect of the serotonin agonist, sumatriptan, on peripheral neurogenic inflammation. Reg Anesth. 1996; 21:219-225.
40. Yildiz O, Cicek S, Ay I, et al. 5-HT,-like receptor-mediated contraction in the human internal mammary artery. J Cardiovasc Pharmacol. 1996;28: 6-10.
41. Maassen VanDenBrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98:25-30.
42. Visser WH, de Vriend RH, Jaspers MW, et al. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology. 1996;47: 46-51.